Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q26822752)
Watch
English
Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
title
Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside
(English)
1 reference
stated in
PubMed
main subject
hepatocellular carcinoma
1 reference
based on heuristic
inferred from title
systemic therapy
1 reference
based on heuristic
inferred from title
author
Omar Abdel-Rahman
object named as
Omar Abdel-Rahman
series ordinal
1
0 references
language of work or name
English
1 reference
stated in
PubMed
publication date
December 2013
1 reference
stated in
PubMed
published in
Journal of the Egyptian National Cancer Institute
1 reference
stated in
PubMed
volume
25
1 reference
stated in
PubMed
issue
4
1 reference
stated in
PubMed
page(s)
165-71
1 reference
stated in
PubMed
cites work
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib in advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sorafenib in liver cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Peptide vaccines for hepatocellular carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FJ.JNCI.2013.08.002
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/J.JNCI.2013.08.002
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3733420
OpenCitations bibliographic resource ID
3733420
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3733420
PubMed publication ID
24207088
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
3733420
ResearchGate publication ID
258425998
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
